Medpace (MEDP) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Medpace (MEDP) do?
Medpace Holdings Inc (MEDP) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Manages Phase I through IV clinical trials for biotechnology and pharmaceutical developers. Operates central laboratories and specialized clinics to collect and analyze patient trial data. It manages clinical drug trials primarily for small and mid-sized biotechnology firms using an internal staff model. It is worth $17.73B on the market and sold $2.84B over the last year.
- Market cap
- $17.73B
- P/E ratio
- 35.2×
- Annual sales
- $2.84B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 08, 2026
MEDP’s flags, in plain English
Each flag is a number from Medpace’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.
Earns Its Keep
Earns 117.9% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Capital Works Hard
Earns 70.8% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.
Low debt
Low debt, only 29% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Runway Is Short
This year's bills are bigger than the cash and assets on hand to pay them. At its current rate of spending, its cash on hand covers only a limited stretch.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about MEDP
How big is Medpace?
Medpace’s market cap is $17.73B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.84B: what customers paid the company over the last year, before any costs.
What is MEDP’s P/E ratio?
MEDP’s P/E ratio is 35.2×. Investors pay about 35.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with MEDP?
The company relies heavily on small and mid-sized biopharma clients that depend on external funding to finance their studies. That is one risk on Medpace’s card. Its first risk flag is Runway Is Short, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Medpace’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MEDP’s filings on SEC.gov. The Margin Monkey is research, not advice.
